 |
|
Integrase Inhibitors |
|
Key Management Information |
| Direct Links to Integrase Inhibitor Info | |
| Key Points | |
| Generic | Brand |
| Raltegravir | Isentress |
| Key Principles of Integrase Inhibitors |
| The integrase inhibitors represent a
new class of antiretroviral therapy which became available as of October
2007. This drug class has proven efficacy against multidrug-resistant
HIV and is approved for treatment experienced patients. This class
of drugs acts by inhibiting the HIV integrase enzyme. The HIV
integrase enzyme allows for insertion of HIV DNA into host cell DNA.
Inhibition of this process results in termination of the reproductive
cycle of HIV. Like any other class of drugs, the integrase inhibitors must be administered with at least 2 other active antiretroviral agents. |
| Click HERE to go to Prescribing Information for raltegravir |
| Links to Antiretroviral Sections (click on anything) |
| Nucleoside & Nucleotide Reverse Transcriptase Inhibitors (NRTI) |
| AZT | ddC | ddI | d4T | 3TC | ABC | FTC | TDF | Combivir | Trizivir | Epzicom | Truvada | Atripla |
| Nonnucleoside Reverse Transcriptase Inhibitors (NNRTI) |
| efavirenz | nevirapine | delavirdine | etravirine |
| Protease Inhibitors (PI) | Boosted Protease Inhibitors |
| saquinavir | indinavir | ritonavir | nelfinavir | amprenavir | lopinavir + ritonavir | atazanavir | fosamprenavir | tipranavir |
| Fusion Inhibitors |
| enfuvirtide |
| Co-Receptor Inhibitors |
| maraviroc |
| Integrase inhibitors |
| raltegravir |
Updated 10.17.2007